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Abstract
The panel of serologic markers for inflammatory bowel 
diseases (IBD) is rapidly expanding. Although anti-
Saccharomyces cerevisiae  antibodies (ASCA) and 
atypical perinuclear antineutrophil cytoplasmic antibodies 
(P-ANCA) remain the most widely investigated, an 
increasing amount of experimental data is available on 
newly discovered antibodies directed against various 
microbial antigens. The role of the assessment of various 
antibodies in the current IBD diagnostic algorithm is 
often questionable due to their limited sensitivity. In 
contrast, the association of serologic markers with 
disease behavior and phenotype is becoming increasingly 
well-established. An increasing number of observations 
confirms that patients with Crohn’s disease expressing 
multiple serologic markers at high titers are more likely 
to have complicated small bowel disease (e.g. stricture 
and/or perforation) and are at higher risk for surgery 
than those without, or with low titers of antibodies. 
Creating homogenous disease sub-groups based on 
serologic response may help develop more standardized 
therapeutic approaches and may help in a better 
understanding of the pathomechanism of IBD. Further 
prospective clinical studies are needed to establish the 
clinical role of serologic tests in IBD.
© 2007 The WJG Press. All rights reserved.
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INTRODUCTION
Serologic response to various microbial and autoantigens 
can develop in inflammatory bowel diseases (IBD). 
In addition to the well-established atypical perinuclear 
antineutrophil cytoplasmic antibodies (atypical P-ANCA) 
and anti-Saccharomyces cerevisiae mannan antibodies (ASCA), 
a number of  new antibodies have recently been discovered 
and data on their clinical significance has been rapidly 
increasing.
The usefulness of  different antibodies in Crohn’s 
disease (CD) and ulcerative colitis (UC) as diagnostic 
markers, follow-up parameters, or as subclinical markers 
in affected families has been actively investigated. Another 
field of  interest is the association of  the serologic markers 
with the disease phenotype, disease course, and treatment 
stratification. The role of  the antibodies in disease 
pathophysiology remains to be fully elucidated.
In this review we discuss current understanding of  
the clinical importance of  various established and newly 
recognized serologic markers in IBD.
SEROLOGIC PANEL FOR INFLAMMATORY 
BOWEL DISEASE
Anti-neutrophil cytoplasmic antibody 
The classic anti-neutrophil cytoplasmic antibody (ANCA) 
tests are used to diagnose and monitor the inflammatory 
activity in primary small vessel vasculitides. On the 
basis of  an international consensus statement, ANCA 
testing is performed with serum samples by indirect 
immunofluorescence (IIF) on normal peripheral blood 
neutrophils. Two basic ANCA patterns are detectable: the 
cytoplasmic (C-ANCA) and the perinuclear (P-ANCA). 
The C-ANCA pattern appears as a granular, diffuse 
cytoplasmic f luorescence, often with accentuated 
fluorescence around the nuclear lobes. Typical P-ANCA 
reactivity results in homogeneous rim-like staining of  the 
perinuclear cytoplasm. ANCA positive serum samples and 
also those with any other cytoplasmic fluorescence or an 
antinuclear antibody (ANA) that results in homogeneous 
or peripheral nuclear fluorescence should be tested 
in enzyme-linked immunosorbent assays (ELISA) 
for proteinase 3 (PR3) and myeloperoxidase (MPO) 
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antibodies, because these are the most common targets of  
C-ANCA and P-ANCA antibodies respectively (Minimum 
recommendation of  consensus group). Ideally, ELISAs 
should be performed on all serum samples, since IIF alone 
detects only 90% to 95% of  all ANCA positive serum 
samples in patients[1]. A third ANCA pattern of  clinical 
importance is the so-called atypical P-ANCA staining. 
It has been suggested that since the target antigens of  
atypical P-ANCA are nuclear rather than cytoplasmic, this 
pattern would be more properly named anti-neutrophil 
nuclear antigen (ANNA). Until the target of  atypical 
P-ANCA reactivity is identified however, it is likely that the 
atypical nomenclature will remain in common use. Atypical 
P-ANCA is recognized as a broad inhomogeneous rim-
like staining of  the nuclear periphery often with multiple 
intranuclear foci[2]. The antigen specificity of  these 
atypical ANCAs are different from the classic C- and 
P-ANCAs, being localized in the nuclear periphery, in 
contrast to the cytoplasmic location of  the classic C- and 
P-ANCAs. Atypical P-ANCAs are most commonly seen 
in patients with IBD, especially ulcerative colitis, and some 
autoimmune liver diseases such as autoimmune hepatitis 
(AIH) and primary sclerosing cholangitis (PSC).
Atypical P-ANCA is present in the sera of  40% to 
80% of  patients with UC[3,4] and to a lesser extent in CD 
(5%-25%)[5]. The prevalence of  the antibody is also high 
in patients with PSC (88%)[6] and AIH typeⅠ(81%)[7], but 
is detected in only 1%-3% of  healthy control subjects. 
Some sera with atypical ANCA reactivity are positive for 
antibodies to elastase, lactoferrin, cathepsin G, lysosyme 
or bactericidal permeability-increasing protein (BPI), but 
since they are only detected in a few atypical P-ANCA 
positive sera,  these antigens do not appear to be the 
primary targets of  atypical P-ANCA reactivity. 
The target antigen(s) of  atypical P-ANCA have not 
been definitively identified. What is in agreement is that 
target antigen(s) are associated with inner side of  the 
neutrophil nuclear membrane. A 50-kilodalton myeloid-
specific protein has been identified by Tejung and appears 
to be the best current candidate as the primary target of  
atypical P-ANCA. Histone H1, which binds to the DNA 
linking nucleosomes, has been suggested as a target antigen 
of  atypical P-ANCA[8]. However, histone H1 is found in all 
cells with nucleus and is not specific to neutrophils. There 
has been little independent support of  this idea. 
Differentiation of  the atypical P-ANCA from the typical 
vasculitis P-ANCA pattern is difficult on ethanol-fixed 
neutrophils. The patterns are most reliably differentiated 
by testing sera on both ethanol and formalin-fixed 
neutrophil slides. The typical P-ANCA pattern converts to 
a cytoplasmic C-ANCA pattern when tested on formalin-
fixed neutrophils, while atypical P-ANCA is mostly 
destroyed by the formalin treatment or presents weak 
homogeneous staining[9]. Despite the above-mentioned 
differences, IBD (and autoimmune liver disease)-associated 
atypical P-ANCA is still often only referred to as P-ANCA. 
This failure to clearly distinguish P-ANCA reactivity 
from atypical P-ANCA reactivity can lead to considerable 
confusion and should be highly discouraged because of  
the different clinical implications of  each result. 
Since the exact target antigen(s) of  atypical P-ANCA 
has not been identified, there are currently no sensitive 
and specific solid-phase assays available to screen for 
these antibodies. IIF is the only widespread method to 
detect the antibodies; however it is technically demanding, 
subjective, and requires experienced observers for good 
interpretation. Joossens et al[10] evaluated the interassay and 
interobserver variability in the detection of  UC-associated 
atypical P-ANCA comparing four different commercially 
available assays. Their results confirmed an earlier 
observation reporting inter-laboratory variability[11]. Not 
all ANCA assays are suitable for the detection of  the anti-
neutrophil cytoplasmic antibodies in IBD patients. The 
differences among the commercially available substrates 
are remarkable and probably result from differences in cell 
preparation, fixation methodologies, and conjugates. In 
addition to substrate differences, ANCA determinations 
and titer assignment are subjective and are highly 
dependent on the expertise of  the observer.  Furthermore, 
unlike the Consensus Recommendations for the vasculitis-
associated ANCAs, there are no clear guidelines for 
immunofluorescence detection and interpretation of  atypical 
P-ANCA patterns. Consequently, different laboratories 
may each observe the same pattern (i.e. the test performs 
consistently), but interpret the pattern differently. 
An alternative methodology for the identification of  
the atypical P-ANCA reactivity developed by Targan and 
associates, uses a 3-step process that includes ELISA 
analysis, IIF assay on methanol-fixed neutrophils, followed 
by another IIF testing on deoxyribonuclease (DNase)-
treated neutrophils. DNase-sensitive P-ANCA (i.e. not 
detectable on DNase-treated neutrophils) is present in 
the sera of  60% to 80% of  the patients with UC and 
approximately 10% to 30% of  patients with CD. In 
approximately 70% of  UC sera, there is ablation of  the 
P-ANCA pattern and the antigen recognition after DNase 
digestion of  substrate cells[12]. This suggests that the 
epitope recognized by the UC-associated atypical P-ANCA 
is a protein-DNA complex or that the presence of  intact 
DNA is necessary for maintaining the integrity of  the 
epitope[4]. In up to 30% of  the sera, there is conversion 
to homogeneous cytoplasmic staining, while in 3% of  
the sera the P-ANCA pattern was retained after DNase 
treatment of  the substrate. 
The overall specificity of  the atypical P-ANCA is 
84%-95%, sensitivity is 48%-63%, positive predictive value 
(PPV) is 69%, and negative predictive value (NPV) is 89%[5]. 
Anti-Saccharomyces cerevisiae antibodies 
Anti-Saccharomyces cer evis iae antibodies (ASCA) are 
ant ibodies directed pr imari ly against a 200 kDa- 
phosphopeptidomannan cell wall component of  the 
common baker’s or brewers yeast’ Saccharomyces (S .) 
cerevisiae[13]. ASCA reactivity could be a result of  cross-
reacting antibodies to antigens found in a non-yeast 
organism and has not yet been identified[14,15]. Mannose 
is not only found in yeast but also in mycobacteria and 
other microorganisms[16]. Both IgA and IgG antibodies are 
formed. Separate and polyvalent ELISA configurations 
are available for ASCA IgG and IgA detection. ASCA 
are more frequently found in CD patients (50%-80%) 
compared to patients with UC (2%-14%) and to normal 
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healthy subjects (1%-7%)[17,18]. Approximately two-thirds 
of  the CD patients with ASCA IgG are also positive for 
ASCA IgA, but 0% to 19% of  the patients have only 
ASCA IgA antibodies. This suggests that both ASCA IgG 
and IgA antibodies should be measured. In CD, up to 90% 
specificity has been reported in specimens positive for 
both ASCA IgG and IgA antibodies, especially when the 
magnitude of  both the IgG and IgA ASCA antibodies is 
high[19]. Sensitivity of  ASCA testing ranges from 41%-76%, 
PPV 88% and NPV 68%[20].
ASCA IgG and IgA levels in CD patients are highly 
variable[19]. The prevalence of  ASCA is much higher in 
cases of  sporadic CD and in families with only CD (63%) 
compared to families with both CD and UC (33%). The 
familial trait to ASCA is obvious, but it is questionable 
whether this is due to the genetic background or 
environmental agents effect in childhood predisposing to 
the disease susceptibility. 
A comparat ive study revealed a wide range in 
sensitivities and specificities among four assays, mainly as 
a consequence of  the cutoff  values chosen. Sensitivity was 
inversely related to specificity and PPV. Results correlated 
well overall and the different ROC curves showed good 
agreement[21].
Newly discovered serologic markers
Anti-OmpC antibody is directed against the outer 
membrane porin C transport protein of  the E. coli. The 
detection of  the IgA antibody is done with ELISA. Anti-
OmpC has been reported in 55% of  CD patients[22], but in 
children and young adults it was only reported 24%[23]. The 
prevalence of  anti-OmpC was insignificant in UC patients 
and in healthy subjects (5%-11% and 5%, respectively). 
Anti-OmpC may be of  value to aid diagnosis of  ASCA 
negative CD patients. The prevalence of  anti-OmpC 
among ASCA negative patients is 5%-15%. 
A fragment of  bacterial DNA (I2), a homolog of  
the tetR bacterial transcriptional factor family, has been 
identified from lamina propria mononuclear cells in 
active CD and shown to be associated with Pseudomonas 
fluorescens[24,25]. Anti-I2 antibody IgA has been detected by 
ELISA in IBD patients with a seroprevalance of  54% in 
CD and 10% in UC. Anti-I2 antibody was also found in 
patients with other inflammatory enteritis (19%) and also 
in healthy subjects (4%)[5].
Serologic expression cloning was used by Lodes et al 
to identify commensal bacterial proteins in colitic mice. 
The dominant antigens were found to be flagellins. Strong 
B-cell and CD4+ T-cell responses were observed against 
one of  these flagellins (anti-CBir1). Colitis was induced 
when the T-cell line specific for CBir1 was transferred 
into naive severe combined immunodeficient mice. 
Approximately 50% of  patients with CD had IgG serum 
reactivity to CBir1 versus 6% of  UC patients and 8% of  
healthy subjects. CBir1 is the first bacterial antigen to 
induce colitis in animal models of  IBD and also leads 
to a pathological immune response in IBD patients[26]. 
Among the population of  CD patients positive for atypical 
P-ANCA, but who do not react to other known antigens, 
40%-44% are  positive for anti-CBir1 whereas the antibody 
has only been found in 4% of  atypical P-ANCA positive 
UC patients. Serum responses to CBir1 may be of  help in 
differentiation between atypical P-ANCA positive CD and 
UC patients independently of  ASCA[27].
Anti-pancreatic antibodies (PAB) are directed against 
the exocrine pancreatic tissue. The exact target antigen(s) 
however, has not yet been identified. The detection of  
PAB is done by IIF on human pancreas substrate. The 
reported prevalence of  PAB is approximately 30% in CD 
patients compared to 2%-6% of  UC patients and 0%-2% 
of  healthy subjects[28]. The relevance of  PAB in the 
pathogenesis of  CD is unclear and whether the presence 
of  PAB identifies a CD subgroup also remains to be 
determined[29].
Patients with CD express antibodies to cell wall 
carbohydrate epitopes found in different pathogenic 
bacteria and fungi. Using a glycan array (GlycoChip) 
and ELISA, anti-glycan antibodies have been found in 
CD patients including anti-laminaribioside carbohydrate 
ant ibody (ALCA) (18%-38%), ant i -ch i tob ios ide 
carbohydrate antibody (ACCA) (21%-36%), and anti-
mannobioside carbohydrate antibody (AMCA) (28%)[30,31]. 
Importantly, 24%-44% of  the CD patients found ASCA 
negative in one study were positive for one or more of  the 
anti-glycan antibodies. Patients with CD who were positive 
for at least one of  ALCA, ACCA, or gASCA (very similar 
to conventional ASCA) could be differentiated from 
UC patients, with 77% sensitivity and more than 90% 
specificity. PPV and NPV was 91% and 77%, respectively. 
When the same criteria were applied to differentiation of  
CD from control patients, the specificity fell to 70.3%[30]. 
As one might expect, combination of  2 or more antiglycan 
antibodies resulted in a higher specificity and PPV in 
differentiation of  CD from UC, but with loss of  sensitivity, 
NPV, and efficiency. These data do not show a great 
increase in the sensitivity and specifity by the glycan assays. 
The low correlation between the presence of  antibodies 
against mannan, laminaribioside, and chitobioside 
suggests that the antigens responsible for these antiglycan 
antibodies are directed against different microorganisms. 
Prevalence of  different serologic markers in IBD and 
their association with the disease phenotype is summarized 
in Table 1. 
DIAGNOSTIC VALUE OF THE SEROLOGIC 
MARKERS IN IBD
The role of  atypical P-ANCA and ASCA as diagnostic 
markers for IBD appears to be limited because of  their 
moderate sensitivity and presence in other conditions. 
Atypical P-ANCA can also be observed in other colitis, 
e.g. collagenous or eosinophilc colitis and in various 
autoimmune liver diseases such as AIH and PSC[32,33]. 
ASCA has been found in AIH (20%) and gastrointestinal 
disorders such as celiac disease[34].
The combination of  atypical P-ANCA and ASCA 
however, may be of  help in patients in whom distinction 
between CD and UC is not obvious with the classic 
diagnostic tools (patient history, radiologic examination, 
endoscopy and biopsy). The ASCA+/atypical P-ANCA- 
serologic pattern is mainly characteristic of  CD, while the 
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ASCA-/atypical P-ANCA+ is characteristic of  UC. Several 
independent studies found that these combinations had 
sensitivities of  from 30% to 64%, specificity more than 
90%, and PPV from 77% to 96%[12,17,18,35,36]. 
It must be emphasized that neither ASCA, nor atypical 
P-ANCA negativity rules out IBD. Similarly, the presence 
of  these antibodies does not confirm the diagnosis of  
IBD. 
Serologic evaluation may be of  help in patients with 
indeterminate colitis (IC) to increase the diagnostic 
accuracy. Ninety-seven patients with IC were enrolled, 
analyzed for atypical P-ANCA and ASCA, and followed up 
prospectively in a multicentre study of  Joosens et al. After 
the 1-year follow-up, a definitive diagnosis was reached in 
31 of  97 patients (37%). In IC patients, ASCA+/atypical 
P-ANCA- results correlated with CD in 80%, whereas 
ASCA-/atypical P-ANCA+ correlated with UC in 63%. 
The remaining ASCA-/atypical ANCA+ patients were 
eventually determined to be CD, but clinically showed a 
UC-like CD phenotype. Remarkably, during the 9.9 year 
follow-up, 48.5% of  the patients did not show antibodies 
against ASCA or atypical P-ANCA. In 85% of  these 
seronegative patients the diagnosis remained indeterminate. 
In contrast, 48% of  the seropositive patients became CD 
or UC on follow-up[37]. Adding anti-OmpC and anti-I2 
to the serologic panel in patients with IC did not add 
diagnostic clarification[38].
Several groups have studied whether atypical P-ANCA 
and ASCA are preclinical markers of  IBD in families. 
Some studies[39,40] showed that presence of  atypical 
P-ANCA occurred frequently in healthy first-degree 
relatives of  UC patients, whereas other studies were not 
able to confirm this observation[41,42]. ASCA positivity was 
obviously found at a higher rate in unaffected first-degree 
relatives of  CD patients than in the general population 
(20%-25% vs 5%)[43,44]. Further studies are necessary to 
clarify whether the unaffected, but ASCA positive, family 
members face an increased risk of  disease development. 
Israeli et al[45] demonstrated that the presence of  ASCA 
and atypical P-ANCA in healthy subjects can predict for 
IBD before the emergence of  overt clinical manifestations. 
Serum samples were obtained systematically and stored 
from 5% of  all military recruits. ASCA were detected in 
31% of  CD patients before clinical diagnosis. The mean 
interval between ASCA detection and diagnosis was 38 
mo. There was no ASCA positivity in control population. 
Atypical P-ANCA was present in 25% of  patients with 
available sera before the diagnosis of  UC. None of  their 
24 matched controls were positive.
ASSOCIATION WITH DISEASE 
PHENOTYPES AND PROGRESSION 
The occurrence of  atypical P-ANCA in UC is associated 
with a characteristic clinical appearance and represents a 
distinct subgroup which is often characterized by specific 
HLA markers. These patients have a higher probability to 
develop a severe left-sided ulcerative colitis, which is more 
resistant to treatment than the usual case. The disease has 
a more aggressive course requiring surgery earlier[47]. Some 
authors suggest that pouchitis develops more frequently 
after ileal pouch anastomosis[48], whereas others were 
not able to confirm this observation. The presence of  
Table 1  Prevalence of different serologic markers in IBD and their association with disease phenotype
Crohn’s disease
(%)
Ulcerative colitis
(%)
Healthy subjects
(%)
Clinical significance
Atypical P-ANCA   2-28 45-82 1-7 Assists in differentiation between CD and UC:
Atypical P-ANCA+/ASCA-: UC
Atypical P-ANCA-/ASCA+: CD
CD: 
ASCA+: ileal involvement, complicated disease course, early need for surgery
Atypical P-ANCA+: left sided colitis, good therapeutical response, 
uncomplicated disease course
UC:
Atypical P-ANCA+: severe left sided colitis, refractory to medical therapy, early
need for surgery
ASCA  41-76   5-15 5
Anti-OmpC
(IgA)
24-55   5-11 5 Identify ASCA- CD patients
Penetrating  disease
Faster disease progression
Early need for surgery
Anti-I2
(IgA)
54 10 4 Inflammatory enteritis (19%)
Stricturing form
Early need for surgery
Anti-CBir1
(IgG)
50   6 8 Flagellin (CBir1) induce colitis in animal models of IBD 
Leads to a pathological immune response in IBD patients
Differentiation between atypical P-ANCA+ CD and UC 
Small bowel involvement
Penetrating and stenosing form
Antiglycan antibodies 36 < 10 0 44% in ASCA- patients
(ALCA ACCA) ALCA-penetrating; ACCA-stenosing  form (small differences)
PAB (IIF) 27-39   2-6 0-2 High specificity, low sensitivity 
Significance?
Distinct CD subgroup?
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atypical P-ANCA identifies a subgroup of  CD patients 
characterized by UC-like colitis; the inflammation usually 
involves the left side of  the colon and the response to 
therapy is generally good. The atypical P-ANCA in CD 
patients associated with later age of  onset and a relative 
decreased incidence of  complications such as stricture 
and/or perforation[49-51].
Phenotype and the disease course of  CD are heavily 
dependent on the presence and extent of  serologic 
responses against various microbial antigens. In patients 
with an ASCA+ (IgG and/or IgA)/atypical P-ANCA- 
phenotype, small bowel involvement (with or without 
colonic disease) is more typical than the pure colonic 
disease (68%-76% vs 34%-46%)[18,51,52]. ASCA positivity 
predicts a more aggressive disease course with a higher 
rate of  complications. ASCAs have been associated with 
stricturing (70%) and penetrating (51%) type of  disease 
as opposed to the inflammatory one (14%) and a higher 
risk of  small bowel resection[46,49,53]. Several studies suggest 
that ASCA positivity is associated with an earlier onset of  
disease[16,48]. ASCA IgA positivity in children may represent 
a higher risk for relapses [OR 2.9 (95% CI 1.33-6.33)][54].
The presence of  anti-OmpC in adult CD patients is 
associated with an increased prevalence of  the penetrating 
form only[21,49,50], while in children both the penetrating and 
stenosing forms[55] are more frequent. Moreover, antibody 
positivity may lead to a more aggressive course of  disease 
and a higher risk for surgical interventions.
Like ASCA and anti-OmpC, anti-I2 also appears to 
be associated with an increased risk for complications 
in adult CD patients. It is an independent risk factor for 
the development of  the stenosing form and the need for 
surgical interventions[21,49,50].
Recent research has shown that the anti-CBir1 antibody 
is associated with ileal involvement in adult CD patients 
independent of  other serologic markers, and it predisposes 
to the development of  both stenosing and penetrating 
forms[26].
Among the anti-glycan antibodies in CD, ALCA is 
more often positive in the penetrating form (34% vs 
25%) and ACCA in the stenosing one (29% vs 18%) 
when compared to the inflammatory type; although, the 
differences are small. No correlation was found between 
the anti-glycan positivity and the need for small-bowel 
resections[30]. 
The number of  antibodies produced against microbial 
antigens in CD shows a positive correlation with the 
severity of  the disease course. Mow et al[50] analyzed 303 
patients retrospectively and found that simultaneous 
presence of  3 antibodies (ASCA, anti-OmpC and anti-I2) 
resulted in an increased risk of  complications [stenosing 
form (72% vs 23%), penetrating form (58.7% vs 27.9%) 
and need for surgical intervention (72% vs 23%)], as 
compared to the seronegative group. When all three 
antibodies were present, the OR was 8.6 (95% CI 4.0-18.9).
In addition to qualitative correlations, quantitative 
correlations with serologic responses are also present. 
Patients expressing serologic markers at high titers are 
more likely to have complicated small bowel CD. In a 
prospective pediatric cohort (n = 196), Dubinsky et al[52], as 
in a related study by Mow et al[50], found that the presence 
and magnitude of  immune responses to microbial 
antigens (ASCA, anti-OmpC, anti-I2 and anti-CBir1) 
were significantly associated with more aggressive disease 
phenotype. The risk of  developing penetrating and/or 
stricturing CD was increased 11-fold in those individuals 
with immune responses to all four microbial antigens 
compared to seronegative cases [95% CI (1.5-80.4)]. 
Moreover, they demonstrated that the time to develop 
a disease complication during the 18 mo of  follow-up 
period was significantly faster in those children who had 
a serologic response against at least one antigen. There 
is a difference between the cohort studies performed in 
children and adults indicating differences as to which 
immune response has the greatest effect on the course 
of  the disease in children and adults. The reason for this 
difference is not yet understood.
An elevated titer of  several antiglycan antibodies also 
predispose to the development of  complicated ileal CD[30]. 
In patients positive for more than 2 anti-glycan antibodies 
(ALCA, ACCA, gASCA), ileal involvement can be seen in 
93% of  the cases, as compared to seronegative patients 
(60%) [OR 9.0; 95% CI (3.3-24.5)]. High ALCA titers 
seem to be correlated with small bowel involvement and 
the development of  stenosing and penetrating disease 
forms. ACCA titers, on the other hand, demonstrated no 
such associations. 
One should be aware that really striking differences in 
serologic response are demonstrated only in a minority 
of  patients. About 1/4 of  the patients are positive for 
several antibodies and have markedly elevated antibody 
titers at the same time. The proportion of  seronegative 
patients, or patients being positive for only 1 antigen with 
a low antibody titer, is about the same. The remaining 
50% of  all CD patients have an intermediate phenotype 
based on the serologic assessments. The aim is to find new 
serologic markers with which we shall be able to identify 
certain homogenous groups of  patients in this grey zone 
regarding disease progression and response to therapy[21,30].
SEROLOGICAL MARKERS IN THE 
FOLLOW-UP AND TREATMENT OF IBD
In patients with UC, no correlation was found between 
the presence and titer of  atypical P-ANCA and the activity 
of  the disease. The titer of  atypical P-ANCA remains 
unchanged even after a colectomy[45]. Similarly, the presence 
of  ASCA in CD patients is relatively constant during the 
course of  the disease and seems to be independent of  the 
disease activity[45,48,51]. As a consequence, neither atypical 
P-ANCA, nor ASCA is suitable for monitoring the disease. 
The ALCA and ACCA titers also seem to be independent 
of  disease activity[30]. The prevalence of  ASCA, anti-I2, 
anti-OmpC, and the presence of  multiple serologic 
responses are more frequent when the disease persists for 
a long time[49,56].
Landers e t a l found that fol lowing anti-TNF-α 
treatment the prevalence and titer of  various antibodies 
(ASCA, atypical P-ANCA, anti-I2 and anti-OmpC) 
remained unchanged in the majority of  patients[30]. 
Mesalamine treatment also leaves the ASCA level 
unchanged in active CD patients[57]. ASCA positivity 
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remains even after steroid treatment, but the antibody titer 
decreases[58].
The role of  the serologic response in the prediction 
of  therapeutical effectiveness is yet to be determined. A 
Belgian study involving 279 CD patients failed to find 
any correlation between the atypical P-ANCA or ASCA 
positivity and the rate of  response of  patients given anti-
TNF-α treatment. The investigators observed a generally 
poorer responsiveness in the case of  atypical P-ANCA+/
ASCA- status, but the difference was not significant[59]. 
Patients exhibiting serologic responses against various 
microbial antigens (OmpC and I2) should expect a 
higher remission rate if  the budesonide treatment was 
supplemented with ciprofloxacin and metronidazole, 
while in anti-OmpC/I2 seronegative group budesonide 
treatment alone proved to be more effective[60]. The 
study brings up the possibility that certain antibiotics are 
more effectively used in those CD patients who present a 
marked immunologic response against microbial antigens. 
This group of  patients may be the one that can be most 
effectively treated by manipulating the bacterial flora.
MUTATIONS OF THE SEROLOGIC 
MARKERS AND RECEPTORS TAKING 
PART IN INNATE IMMUNITY
Genetic heterogeneity may be responsible for the 
differences found in the serologic response. Literature is 
split regarding the possible correlation between antibody 
production in patients with CD and the NOD2/CARD 
15 status. Several studies found the serologic response 
(atypical P-ANCA, anti-I2, anti-OmpC, ASCA IgG/IgA) 
to be independent of  the NOD2/CARD 15 status[50,53]. 
A Belgian workgroup, on the other hand, confirmed 
the proposed association in a large (n = 913) cohort of  
patients. When more than 1 NOD2/CARD 15 mutation 
was present, the investigators found the rate of  gASCA 
positivity and its titer to be significantly higher. Moreover, 
they found a positive correlation between the number 
of  mutations and the prevalence of  gASCA and ALCA, 
which may indicate a gene dose effect[61].
Invest igat ing the associat ion of  the serologic 
response with the toll-like receptor (TLR)-4 gene D299G 
(Asp299Gly) polymorphism led to results in contrast to 
those found with the NOD2/CARD 15 assessments. 
If  the patient had a variant TLR-4 genotype, the rate 
of  ACCA positivity was less frequent as compared to 
the wild type, which again suggests a gene dose effect. 
Polymorphism may also play a role in the development 
of  serologic responses against the Gram-negative E. coli 
membrane protein. The Belgian workgroup also found a 
correlation between anti-Omp positivity and TLR4 gene 
polymorphism in patients with UC (n = 272)[59]. Anti-Omp 
positivity was significantly less frequent among patients 
with a TLR4 variant genotype and prevalence of  the 
antibody showed an inverse correlation with the number 
of  the variants[58].
It must be mentioned that the immune response 
against microbial antigens seems to be more closely 
correlated with disease phenotype and the frequency of  
complications in CD than the known predisposing genetic 
factors.
SEROLOGIC MARKERS IN THE 
PATHOPHYSIOLOGY OF IBD
The real impor tance of  the ant ibodies produced 
against various microbial and autoantigens is sti l l 
unclear. A fundamental question that remains to be 
answered is whether these antibodies play a role in the 
immunopathogenesis of  IBD, or their appearance is 
merely a consequence of  the inflamed, leaky bowel 
mucosa. Several studies suggest that the main reason for 
the antibody production is loss of  the immune tolerance, 
rather than increased bowel permeability[48,62]. Clinical 
studies could not find any correlation between the 
serologic response and bowel permeability in CD patients, 
suggesting that the presence of  different serologic markers 
is not an epiphenomenon related to disease activity[21,45,48,51].
Lindbergh et al[63] demonstrated that CD was associated 
with a high serologic response against yeast and mannose, 
but no antibodies were produced against food antigens. 
Konrad et al[64] found strong and specific lymphocyte 
reaction against mannose in ASCA positive CD patients, 
but not against the nutritional antigen, ovalbumin. Both 
studies concluded that the serologic response in CD is a 
highly selective process against certain antigens and not a 
generalized immune hyperreactivity against the intestinal 
content.
Dubinsky et al[52] reported that the immune response 
against bacteria is not a consequence of  the transmural 
penetration, since it develops earlier. It remains, however, 
an open question as to what was the extent of  the immune 
response before the onset of  the complications in the 
symptom-free patients, where no serologic assessments 
were performed due to the lack of  clinical signs. Results 
of  this study coincide with earlier observations that the 
presence of  serologic response in a given patient does not 
change during the course of  disease. 
The currently accepted theory for the etiopathogenesis 
of  IBD suggests that susceptibility to the disease, the 
clinical manifestations, and the progression depend equally 
on genetic factors, impairment of  immune regulation, and 
environmental effects. The chronic inflammation of  the 
intestinal mucosa and the related systemic reactions in IBD 
are consequences of  an exaggerated immune response 
against the endogenous gut flora.
When the immune and/or bar r ier function of  
the bowel mucosa are genetically impaired, certain 
environmental factors may easily initiate a pathologic 
process. Animal models[65-67] highlight the importance of  
the interaction between host and its intraluminal bacteria. 
In the presence of  a particular genetic defect, not every 
member of  the commensal bacterial f lora is able to 
induce pathologic immune response and the extent of  the 
serologic reaction-and thus the clinical appearance of  the 
disease-may differ. A higher rate of  antibody production 
may reflect the extent of  loss of  tolerance against the 
various microbial antigens. A clinical interpretation of  
this observation may be that the effect of  bacteria on the 
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prevalence and extent of  the inflammatory reaction may 
affect the course of  disease. Loss of  immune tolerance in 
CD develops against targeted microbial and autoantigens 
and is not a global process[52].
CONCLUSION
ASCA and atypical P-ANCA remain the best-characterized 
markers in IBD. Unlike ASCA assays, which are generally 
ELISA tests and both simple to run and well-standardized, 
atypical P-ANCA testing is dependent on experienced 
personnel for both running and interpreting the test 
results. Results of  the various assays used for the detection 
of  atypical P-ANCA may differ significantly from each 
other and must therefore be compared very carefully. 
Individually ASCA and atypical P-ANCA tests have 
moderate sensitivity and specificity. Atypical P-ANCA 
and ASCA cannot be used for monitoring, because the 
antibody titers are relatively stable and do not correlate 
with disease activity.
Assessing both ASCA and atypical P-ANCA reactivity 
allows better differentiation of  CD from UC and from 
non-CD than using the individual tests alone. The ASCA+/
atypical P-ANCA- phenotype is characteristic of  CD, while 
the ASCA-/atypical P-ANCA+ phenotype is seen primarily 
in UC. Viewed together, the two assays offer a differential 
diagnostic tool, which may be particularly helpful in those 
cases when the diagnosis of  CD or UC cannot be safely 
established using conventional investigation methods 
(medical history, radiological assessments, endoscopy and 
biopsy). These markers can help in the assessment of  
about half  of  the patients in the indeterminate colitis (CD 
or UC) category. In Crohn’s disease ASCA positivity carries 
a higher chance of  a complicated disease behavior and the 
need for early surgical intervention. In UC the presence of  
atypical P-ANCA one can expect a dominantly left-sided 
disease, which is often severe and resistant to therapy, with 
a high risk of  early surgical intervention.
Newer markers derived from various microbial 
inhabitants of  the gut, such as Omp, I2, and CBir1, as 
well as various glycan markers offer new ways to stratify 
patients into serologic subgroups. The cumulative presence 
and extent of  the serologic response against these various 
markers may act as prognostic indicators of  the severity 
and behavior of  the ileal disease. Although the prevalence 
of  antibodies is higher in healthy relatives of  IBD patients 
than in the control population, their role as subclinical 
markers is yet to be established.
There is considerable overlap of  the reactivity of  many 
of  the new serological markers and additional studies to 
more fully understand the basis for their development as 
well as their clinical significance are required. Addition 
of  these, as well as yet to be discovered new markers, to 
the serologic IBD diagnostic algorithm will likely result in 
incremental increases in sensitivity. Increases in sensitivity 
however, can often be accompanied by reductions in 
specificity and this outcome must be carefully assessed 
and recognized. Evolution of  effective serological test 
panels will involve shifting through the various markers to 
arrive at optimal diagnostic utility balanced with practical 
economic realities. 
We have made significant progress in understanding the 
clinical features associated with various serologic markers 
in IBD. The ongoing challenge is how to best utilize these 
new assays to provide clinically relevant information in 
a cost-effective manner. Assembly of  logical panels of  
serologic markers to identify patients at increased risk 
of  more severe disease and who may benefit from early 
intensive monitoring and therapy to improve long-term 
outcome is a primary practical goal. Further prospective 
clinical trials will be needed to determine the evolving role 
and practical clinical importance of  serologic assessments 
in IBD. 
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